ONCOSEC MEDICAL Inc: Nasdaq/NYSE listing notice — OncoSec receives Nasdaq delisting notice after Chapter 7 filing; trading suspended June 26

ONCOSEC MEDICAL Inc

Nasdaq Staff determined to delist OncoSec due to Chapter 7 bankruptcy filing (June 14) and public interest concerns.
Company failed to meet minimum $2.5M stockholders' equity (Rule 5550(b)(1)) and bid price above $1.00 (Rule 5550(a)(2)).
Trading of common stock (ONCS) will be suspended at opening on June 26, 2023; Form 25-NSE to follow.
Company does not intend to appeal the Staff's determination.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

ONCOSEC MEDICAL Inc received a nasdaq delisting notice notice regarding other (rules 5550(b)(1), 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5550(b)(1), 5550(a)(2)

Exact text from the filing

June 15, 2023, the Chapter 7 bankruptcy trustee (“Trustee”) for OncoSec Medical Incorporated (the “Company”) received a letter from the staff of the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company and the Trustee that the Staff has, in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, determined that the Company’s securities will be delisted from Nasdaq based on the following factors: (i) on June 14, 2023, the Company filed for protection under Chapter 7 of the U.S. Bankruptcy Code (the “Chapter 7 Filing”) and the associ

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-23-022077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.